Articles tagged with Antibody Therapy
Researchers developed a neurodevelopmental chick model that demonstrates fetal death and brain damage similar to microcephaly caused by the Zika virus. The study suggests that identifying critical windows of susceptibility could lead to therapeutic innovation.
Research on therapeutic antibodies for spinal cord injury reveals potential applications in myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction. Several antibodies are reviewed as reagents to promote neurite outgrowth and inhibit immune responses.
Selecta Biosciences' synthetic vaccine particles have been shown to induce antigen-specific immune tolerance, mitigating the formation of anti-drug antibodies and improving the efficacy and safety profile of biologic drugs. The technology has potential applications in treating rare diseases, allergies, and autoimmune diseases.
Researchers found that combining anthrax toxin proteins with chemotherapy drugs can selectively target blood vessel cells feeding tumors, reducing tumor growth. The treatment regimen showed durable anti-tumor effects in mice, warranting further exploration for cancer therapy.
Scientists at Aarhus University used X-rays to study eculizumab's mechanism. They found the antibody creates a physical barrier preventing C5 cleaving enzymes from forming contacts.
A research team has identified a new group of powerful antibodies to fight Ebola virus, isolated from the blood of a survivor of the 2014 Ebola outbreak. The antibodies showed significant protection against the virus in mouse models and could guide the development of a vaccine or therapeutic.
Researchers at Adimab isolated a broad panel of neutralizing anti-Ebola virus antibodies from a survivor of the 2014 outbreak. The study highlights the speed and effectiveness of Adimab's single B cell isolation platform, which was able to identify over 300 monoclonal antibodies within weeks of receiving a blood sample.
Researchers developed an antibody targeting a hormone in adipose tissue called aP2 to improve glucose regulation and reduce liver fat in obese mice. The study found that one of the antibodies effectively improved glucose regulation in two independent models of obesity, with beneficial reductions in liver fat.
Researchers discovered that anti-PlGF antibody treatments, such as aflibercept, may slow the progression of dry age-related macular degeneration. The study found that PlGF actually worsened retinal damage in mice, but an anti-PlGF treatment provided protection against light-induced degeneration.
Researchers discovered a malaria protein that binds to a common sugar molecule found on both placentas and cancer cells. A novel technology was developed to arm antibodies with high potency toxins to specifically kill cancer cells, showing promising results in clinical trials.
A novel two-hit therapy combining an immune-molecule-based mop-up therapy with a pathway-disabling approach eradicates specific breast tumors in mice. This therapy has the potential to reduce treatment costs and increase effectiveness for Her2-positive breast cancers.
Researchers developed targeted therapy using immunoglobulin-A antibodies to neutralize specific receptors in polycystic kidneys. The strategy enables repurposing of existing monoclonal antibodies for PKD therapy, opening up new class of therapeutics.
Zhiqiang An received a grant to research how tumors evade therapy, aiming to develop countermeasures for improved immunotherapy success and reduced mortality. The focus is on a type of leukemia affecting tens of thousands in the US.
Dr. Qizhen Shi's team aims to investigate a novel gene therapy approach that induces immune tolerance for hemophilia A, overcoming the challenge of inhibitory antibodies. The project seeks to develop a clinically translatable gene therapy protocol that provides therapeutic FVIII protein.
Researchers at Rockefeller University have discovered two antibody-binding receptors on immune cells that work together to kill tumors and create a memory of them. The study found that targeting specific antigens with antibodies can lead to the formation of immunological memory, which can suppress future tumor growth.
Researchers found that camel antibodies protected uninfected mice from MERS and helped infected mice expunge the disease. The study suggests these antibodies might be therapeutic for MERS patients and protect uninfected household members and healthcare workers.
Scientists have identified antibodies isolated from individuals with seasonal flu vaccinations that neutralize H7N9 and other influenza strains, providing broad protection. These antibodies account for a small percentage of the total immune response but show promise as potential therapeutics.
Researchers fuse human hormones with cow antibodies to create long-lasting treatment options for hormone deficiencies and other diseases. The new therapy shows promise in reducing the frequency of injections needed for conditions like Turner syndrome and low birth weight.
Solvanix will work with biotech and pharmaceutical companies to develop customized solutions for stability issues in therapeutic monoclonal antibodies. The new technology improves antibody stability by altering specific regions without compromising its human quality.
Researchers from Uppsala University developed a therapeutic vaccine that selectively targets tumor vessels, reducing tumor burden and suppressing metastases in a mouse model of metastatic breast cancer. The vaccine induced an 80% reduction in metastasis, providing a cost-efficient alternative to monoclonal antibody-based therapies.
A recent study developed an AAV-based medication that offers substantial protective effects for patients attempting to cease methamphetamine use. The treatment, which tightly binds and sequesters meth away from its sites of action in the brain, is non-addicting and suitable for use in combination with existing behavioral therapies.
A pilot observational study found proactive monitoring and dose adjustment of infliximab resulted in fewer disease recurrences and infusion reactions. The authors propose routine monitoring of IFX concentrations and adjusting doses based on levels for patients with IBD.
Researchers from NYU Langone will present new findings on tau immunotherapy and its potential for treating Alzheimer's disease. The presentations focus on the role of mitochondria and death receptors in amyloid toxicity, which may lead to improved treatment options for patients.
Researchers at the University of Texas Medical Branch have developed a human monoclonal antibody, m102.4, that protects nonhuman primates from Nipah virus disease even five days after infection. This breakthrough could lead to the development of a therapeutic treatment for people infected with the deadly virus.
Researchers discovered that shark antibodies possess structural characteristics making them robust against dehydration, leading to enhanced stability in human antibody fragments. This breakthrough enables the development of improved therapeutic and diagnostic antibodies with increased efficacy.
A phase 3 study found that evolocumab, a human monoclonal antibody, added to moderate- or high-intensity statin therapy further lowers LDL-C levels by up to 24 percent. The treatment was well-tolerated and showed similar results across different statin types and doses.
Scientists have found that targeting adhesion molecule CD146 with anti-CD146 antibody AA98 shows promise in reducing inflammation and tumor incidence in mice with colitis. The study suggests that CD146 plays a dual role in promoting inflammation, making it a potential therapeutic target for treating inflammatory bowel disease and preve...
Scientists at the University of Sheffield have developed a novel antibody-based therapy to target fibrosis progression. The treatment blocks key enzyme action and may also work for lung, liver, and heart fibrosis.
Researchers at LA BioMed developed antibodies to prevent human cell invasion and treat mucormycosis using CotH protein blocker. The study provides groundwork for developing therapies and diagnostic tests for high-risk patients.
Researchers have discovered that monoclonal antibodies can effectively treat HIV by directly targeting free virus and virally infected cells. The treatment resulted in rapid decline of virus levels in monkeys and boosted their immune responses against the virus, offering a potential new therapy option for humans.
Researchers have discovered anti-tau antibodies that can prevent the accumulation of toxic tau proteins, improving cognitive function and reducing pathology in mouse models. The findings suggest a potential basis for treating Alzheimer's disease and other neurodegenerative disorders.
Researchers developed a monoclonal antibody effective against human norovirus, which can prevent infection in susceptible host cells. The study aims to explore the antibody as both treatment and disease prevention strategy for outbreaks, particularly among vulnerable populations like healthcare workers and travelers.
Richard Lerner's discovery of combinatorial antibody libraries has led to the development of two market-leading drugs, Humira and Benlysta, alleviating suffering from autoimmune diseases. His work has significantly impacted disease treatment and prevention, showcasing his dedication to advancing human health.
US Army researchers have successfully tested antibody-based therapies in monkeys infected with Ebola and Marburg viruses, demonstrating full protection even when treatment was delayed until two days post-infection. This breakthrough provides proof-of-concept for developing filovirus therapies for human use.
Researchers found that rituximab, a monoclonal antibody, was safe and effective in reducing liver damage in PBC patients who had an incomplete response to UDCA therapy. The study showed significant reductions in alkaline phosphatase levels and anti-mitochondrial antibodies after treatment.
A collaborative research team has developed an effective therapy against Hendra virus, giving an anti-virus human monoclonal antibody therapy after exposure protected animals from lethal disease. The study demonstrates promising results and offers a real potential treatment for Hendra virus infection in people.
A neutralizing human monoclonal antibody, m102.4, has been developed to protect against Hendra virus infection, showing promise as a potential treatment for severe illness and death in humans. The antibody attacks a critical component of the virus, preventing its infection of cells.
Three Ontario projects focused on biomonitoring, gene function, and synthetic antibody production will further knowledge and discovery in these fields. The funding will support the creation of new methods to monitor environmental change and improve treatment options for cancers.
Researchers generated mice with a human immune system using human stem cells, allowing them to produce human monoclonal antibodies. This breakthrough could simplify the study and treatment of diseases.
A review suggests that many cases of treatment-resistant severe asthma in children are due to poor management, including adherence issues and environmental triggers. The authors recommend a multidisciplinary approach to confirm diagnosis, address comorbidities, and develop an individualized treatment plan.
A phase III clinical trial found that ipilimumab, a monoclonal antibody, significantly extended the lives of patients with metastatic melanoma. The therapy showed a 67% increase in survival time compared to those receiving gp100 alone, demonstrating its promise as an alternative treatment for cancer patients.
Researchers at Arizona State University have developed a plant-based therapeutic that effectively combats West Nile virus infection. The treatment, derived from tobacco plants, neutralizes the virus by binding to its surface protein, offering a promising alternative to existing treatments.
Researchers at USU and Australian Animal Health Laboratory demonstrate effective therapy against Nipah virus using a human monoclonal antibody, m102.4. The treatment showed promising results in animal models, offering hope for preventing and treating diseases caused by the deadly viruses.
Researchers have discovered genetic biomarkers relevant to CRC, allowing for personalized medication and improved survival rates. The integration of conventional agents with novel targeted therapies has led to median overall survival exceeding two years in metastatic CRC.
A new study examined cases of TB associated with anti-TNF therapy and found that the risk of TB is higher for patients receiving anti-TNF monoclonal antibody therapy. The study also showed that the risk of TB was higher during the first year of anti-TNF treatment, favoring the reactivation of latent TB.
A new method allows for the detection of multiple immune parameters from individual human cells, which may aid in diagnosing diseases such as type 1 diabetes. This breakthrough enables researchers to study rare blood cells and their role in autoimmune diseases, leading to potential novel biomarkers for therapy monitoring.
A new study found that 30.1% of patients with refractory rheumatoid arthritis achieved disease remission with tocilizumab plus methotrexate. The treatment showed significant clinical improvements in efficacy and safety, with low rates of serious adverse effects.
A Phase 3 study demonstrated significant improvements in signs and symptoms, physical function, and disease activity in RA patients who received golimumab after being previously treated with anti-TNF agents. The study showed sustained improvements through six months.
Golimumab shows significant improvements in physical function, disease activity, and remission rates in patients with active RA despite ongoing treatment with MTX. The combination therapy also achieves clinically relevant improvements in HAQ scores.
The study analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program and found that non-Hodgkin lymphoma patients showed significant improvements in five- and 10-year survival rates, with increases ranging from 26.8 to 27.1 percentage points across all age groups and tumor subtypes.
Patients with painful and progressive ankylosing spondylitis showed significant improvements in physical function and symptoms after golimumab treatment, with 51-66% achieving ASAS 20 or 40 at six months.
Melvin Berger, a University Hospitals researcher, received a $250,000 grant to study the effectiveness of an under-the-skin pump versus an intravenous drip for treating patients with neurological diseases. The goal is to reduce side effects and increase patient treatment options.
Researchers discovered that a small fraction of IgG antibodies in IVIG carry sialic acid, responsible for its anti-inflammatory effects. The team enriched IVIG for these molecules, increasing its activity by a factor of ten and paving the way for a new class of therapeutics.
Xencor's engineered antibody Fc variants show enhanced effector functions, killing tumor cells 10 times more toxic than conventional treatments. These advancements hold promise for developing next-generation antibody therapeutics.
Researchers at GlycoFi have successfully produced human-glycosylated antibodies in yeast, improving cell killing and drug characteristics. This breakthrough allows for unprecedented control and uniformity of glycosylation, enabling optimization of therapeutic proteins.
Recent studies have shown that combining standard chemotherapy with new monoclonal antibody therapies can significantly improve survival rates for patients with follicular lymphoma. The latest study, led by Richard I. Fisher, found a 91% four-year survival rate for patients treated with this regimen.
The need for consensus on IVIG dosing and frequency arises as its use expands, with infusion nurses playing a crucial role in achieving best results from therapy. The article highlights the importance of developing guidelines that maximize patient benefit and minimize risk, given the unique response to different IVIG products.
Researchers found that asymptomatic autoimmune hepatitis patients had lower liver enzyme and IgG antibody levels, but did not differ from symptomatic patients in terms of inflammation. Despite treatment recommendations, most asymptomatic patients do well without immunosuppressive therapy as long as they remain asymptomatic.
Scientists have made a significant breakthrough in understanding pemphigus, a deadly skin blistering disease. Researchers engineered antibodies that reproduce the disease in vitro and in mice, offering a new opportunity for targeted therapy development.
A small trial found that daclizumab add-on therapy reduced the severity and number of brain lesions in patients with relapsing-remitting or secondary progressive multiple sclerosis. The treatment, which blocks the interleukin-2 receptor on immune cells, showed unexpected clinical benefits in a small group of patients.